A phase II, open-label, multicentre study to evaluate the pharmacodynamic profile, the efficacy and the safety of a 6-month sustained-release formulation of triptorelin in patients with prostate cancer.
Latest Information Update: 18 Jul 2011
At a glance
- Drugs Triptorelin (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- Sponsors Beaufour Ipsen Pharma
Most Recent Events
- 18 Jul 2011 New trial record